Steven Nathan, MD, discusses breakthrough treatments for idiopathic pulmonary fibrosis. There are several agents with new mechanisms of action in the pipeline for idiopathic pulmonary fibrosis (IPF).
Recent results from the TETON-1 phase 3 clinical trial assessing inhaled treprostinil to treat idiopathic pulmonary fibrosis ...
BECHTELSVILLE, Pennsylvania (WPVI) -- Most of us take breathing for granted. But with pulmonary fibrosis, patients lose that despite the best medical efforts. That outcome is on the verge of change.
Add Yahoo as a preferred source to see more of our stories on Google. A 3D illustration of human lungs. The Food and Drug Administration on Tuesday approved a new drug for idiopathic pulmonary ...
In a small pilot study, researchers from North Carolina State University have demonstrated a rapid, simple way to generate large numbers of lung stem cells for use in disease treatment. This method of ...
Researchers cracked the complete genetic code of individual cells in healthy and diseased human lung tissues to find potential new molecular targets for diagnosing and treating the lethal lung disease ...
US-based biopharmaceutical company Rein Therapeutics has dosed the first subject in a Phase II trial of LTI-03, its lead asset for treating idiopathic pulmonary fibrosis (IPF). The double-blind, ...
IPF is a rare, progressive and fatal lung disease with a median survival of 2-5 years. 1 Pirfenidone is one of only two drugs approved to treat IPF, and for those patients able to tolerate treatment, ...
NASHVILLE, Tenn. and CAMBRIDGE, England, May 13, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new ...
The randomized Phase 2b ASPIRE trial successfully completed planned enrollment of over 360 patients, reflecting strong execution and robust site engagement ASPIRE is designed to assess the effect of ...
Trevi Therapeutics Investor and Analyst Day May 7, 2026, Midtown New York, New York 10:00 a.m. to 12:00 p.m. ET, followed by lunch and open discussions Representatives: Trevi senior management will be ...
LTI-03 is designed to protect and restore the function of the oxygen uptake cells and control lung fibrosis. Credit: SewCreamStudio / Shutterstock. US-based biopharmaceutical company Rein Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results